Posters

Long term outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization

Poster Details

First Author: C.Calvo SPAIN

Co Author(s):    M. Jimenez   J. Fernandez-Vigo   J. Reche   I. Flores                    

Abstract Details



Purpose:

To compare the long term visual outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization (CNV)

Setting:

retrospective, nonrandomized, consecutive, interventional case series study conducted on 61 eyes of 56 patients.

Methods:

61 eyes of 56 patients with CNV secondary to pathologic myopia treated with intravitreal ranibizumab were retrospectively analyzed. In 26 eyes, treatment was a single injection and further treatment was given pro re nata (group 1+ PRN) while the remaining 35 eyes first received three consecutive monthly injections followed by further treatment PRN (group 3+ PRN). In each participant, demographic data, best-corrected visual acuity (BCVA), CNV recurrence and total number of injections were recorded.

Results:

Mean follow up was 53 ± 16 (24 - 91 months). BCVA values were 51.9 ± 16.2 letters in 3+ PRN and 53 ± 22.4 letters in 1+ PRN at baseline (p=0.824), and 69.5 ± 12.3 and 69 ± 15.1 letters respectively at 12 months, 66.6 ±16.5 and 67.7 ± 13.6 letters at 24 months, and 67.1 ± 16.2 and 66.4 ± 19.7 letters at end follow up, with no differences detected between groups (p=0.877). Also respectively for groups 3+ PRN and 1+ PRN, mean number of injections was 6.1 ± 4.1 and 3.2 ± 2.1, and mean survival until first retreatment was 36.9 ± 6.1 and 19.2 ± 5.4 months (both p<0.001). Baseline BCVA, age, number of injections and CNV location emerged as predictors of final BCVA (all p<0.05).

Conclusions:

The two dosing regimens gave rise to similar visual outcomes. However, in eyes given a single initial injection, retreatment was needed appreciably earlier.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy